Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Local Neostigmine for Snoring
NCT03316963Phase 1Terminated
- Sponsor
- Emory University
- Start
- Nov 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of neostigmine in primary snoring, sponsored by Emory University. Primary endpoints: Change in decibel sound after injection of neostigmine up to 30 days and Change in soft palate motion after injection of neostigmine up to 30 days. Started Nov 2017; status: terminated.
02
Drugs
neostigmine
03
Conditions
primary snoring
Beyond the preview
Go deeper on NCT03316963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03316963.